Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 1997

View Archived Issues

Milkhaus reports results of leukemia trial

ImClone reaches milestone in small cell lung cancer treatment collaboration

Multikine progresses in clinical trials

DynaGen licenses smoking cessation technology

Update on Immunomedics diagnostic imaging products

Immunex reports anticancer activity of Flt3 ligand

FDA approves generic version of Diamox

Schering-Plough Research Institute reveals structure of enzyme in HCV life cycle

Maxygen: new biotechnology company

Fujisawa discloses agents for bone metabolism disorders

Takeda describes GnRH antagonists

Fibrinogen antagonists from Merck & Co.

Preparation and use of 5alpha-reductase type 1 inhibitors described by Merck & Co.

Agents for HIV, tumors and autoimmune diseases from Boehringer Mannheim

New influenza vaccine prepared by Yissum

Anti-HIV vaccines reported by Duke University

Olanzapine superior to haloperidol against negative symptoms in schizophrenia

Body weight positively correlated with cognitive performance in AD

First approval for new MRI contrast agent from Nycomed

Promising animal data reported for Mitsui Toatsu cerebroprotectant

LXR refocuses Lexirin development

r-metHuSCF + filgrastrim for PBPC mobilization and transplantation: a phase I/II trial

Potent LT biosynthesis inhibitors described by Abbott

Clinical trials for Albuterol Spiros completed

Lilly describes potent new SERM

Alpha2-antagonist effective in patients with Parkinson's disease

COMT inhibitor increases response to L-DOPA in patients with PD

Target enrollment reached in phase III trial of Interferon's Alferon N Injection

Tolerance to benzodiazepine hypnotics overcome with melatonin

Selective tumor targeting reported for Bexxar

Phase III results with Lilly's raloxifene reported

Encouraging phase II data with Connetics' ConXn reported

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...